CVBT is committed to exploring medical applications for our drugs which contain the active pharmaceutical ingredient of FGF-1. To achieve this goal, we conduct ongoing research and continually collaborate with internationally recognized researchers in the areas of angiogenesis and growth factors.

We place a high priority on communicating information about our clinical trials to physicians, patients, investors, and other interested parties.

CVBT has posted protocol information for its Phase II severe coronary heart disease (CHD) clinical trial on this website. For additional information regarding this trial as well as our other trials, you may also visit the National Institutes of Health's (NIH) ClinicalTrials.gov website at www.clinicaltrials.gov.

Use of this site constitutes agreement to our Terms and Conditions
and Privacy Policy. Site Design and Contents © 2010 CardioVascular BioTherapeutics, Inc. All Rights Reserved.

Some content on this site requires the free Adobe Reader.